Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

June 19, 2020June 19, 2020

Rituximab More Beneficial if Given to gMG Patients Early, Study Finds

News

Rituximab seems to be more effective in newly-diagnosed patients with generalized myasthenia gravis (gMG), compared to people at more advanced stages of the disease, a study has found. Investigators ... Read more

April 21, 2020April 21, 2020

UCB Acquires Ra Pharma, Adds Zilucoplan to Its MG Pipeline

News

UCB has completed its acquisition of Ra Pharmaceuticals, priced at about $2.3 billion, meaning that zilucoplan — an investigational treatment for myasthenia gravis (MG) — is being added to ... Read more

January 21, 2020January 21, 2020

Scientists Create 3-D Model to Study Neuromuscular Disorders, Including Myasthenia Gravis

News

Scientists have created — in a lab dish — a three-dimensional model system made of human neurons and muscle cells that can be used to study neuromuscular disorders, including myasthenia ... Read more

November 21, 2019November 21, 2019

Difficult-to-treat MG Affects Working Hours and Employment Status, Study Finds

News

People with refractory myasthenia gravis — those whose symptoms persist after treatment — are more likely to miss working hours and to be unemployed than those whose disease responds ... Read more

October 3, 2019October 3, 2019

First Patient Dosed in Phase 3 Trial of Zilucoplan, Ra Pharma Announces

News

Ra Pharmaceuticals announced the first patient enrolled in RAISE, the company’s Phase 3 clinical trial assessing the effectiveness of zilucoplan as a therapy for generalized myasthenia gravis (gMG), has ... Read more

September 24, 2019September 24, 2019

Long-Term Use of Gabapentin May Trigger MG Exacerbations, Case Report Says

News

Physicians should keep in mind that severe exacerbations in patients with myasthenia gravis (MG) might be triggered by the use of gabapentin (sold under the brand name Neurontin, among ... Read more

September 5, 2019September 5, 2019

FDA Grants Orphan Drug Status to Ra Pharma’s Zilucoplan as Potential MG Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zilucoplan, Ra Pharmaceuticals‘ lead candidate for the treatment of myasthenia gravis (MG). This status helps to support the ... Read more

September 3, 2019September 3, 2019

MG Metabolic Profile May be Used as Diagnostic, Prognostic Biomarker, Study Says

News

Scientists discovered that patients with myasthenia gravis have a unique metabolic profile that can be used to diagnose the disorder, but also to predict the course of the disease ... Read more

August 27, 2019August 27, 2019

Juvenile MG Should be Considered When Diagnosing Children with Ocular Abnormalities, Case Report Says

News

Despite being relatively rare in toddlers, juvenile myasthenia gravis should be considered in the differential diagnosis of children showing different types of eye-related symptoms, a case report says. The case ... Read more

August 22, 2019August 22, 2019

In China, Patients with Rare Diseases Struggle for Affordable Therapies, Study Says

News

Despite the support from basic health insurance, those in China living with rare diseases, such as myasthenia gravis (MG), hemophilia, and phenylketonuria (PKU), still struggle to have access to ... Read more

Pin It on Pinterest